Pitavastatin: Finding its place in therapy

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 2, 2011, Pages 101-117

  Ose, Leiv ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

cardiovascular; dyslipidaemia; hypercholesterolemia; lipid; pitavastatin; statin

Indexed keywords

ATORVASTATIN; CYCLOSPORIN A; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INFESTATION; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; MYOSITIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SMOOTH MUSCLE FIBER;

EID: 79960065080     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622310389227     Document Type: Review

References (105)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288: 2998–3000.
2. American Diabetes Association. (2003) Management of dyslipidemia in adults with diabetes. Diabetes Care 26(Suppl 1): S83–S86.
3. Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T. et al. (1997) Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47: 904–909
4. Baigent C. Keech A. Kearney P.M. Blackwell L. Buck G. Pollicino C. et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (9493): 1267–1278.
5. Bailey K.M. Romaine S.P. Jackson B.M. Farrin A.J. Efthymiou M. Barth J.H. et al (2010) Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: The GEOSTAT-1 Study. Circ Cardiovasc Genet 3: 276–285.
6. Barter P. Gotto A.M. LaRosa J.C. Maroni J. Szarek M. Grundy S.M. et al (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357: 1301–1310.
7. Budinski D. Arneson V. Hounslow N. Gratsiansky N. (2009) Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 4: 291–302.
8. Chasman D.I. Posada D. Subrahmanyan L. Cook N.R. Stanton V.P. Jr Ridker P.M. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 1291 (23): 2821–2827.
9. Colhoun H.M. Betteridge D.J. Durrington P.N. Hitman G.A. Neil H.A. Livingstone S.J. et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364: 685–696.
10. Couvert P. Giral P. Dejager S. Gu J. Huby T. Chapman M.J. et al (2008) Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9 (9): 1217–1227.
11. Crouse J.R. 3rd Raichlen J.S. Riley W.A. Evans G.W. Palmer M.K. O'Leary D.H. et al (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 297: 1344–1353.
12. de Lemos J.A. Blazing M.A. Wiviott S.D. Lewis E.F. Fox K.A. White H.D. et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307–1316.
13. Economides P.A. Caselli A. Tiani E. Khaodhiar L. Horton E.S. Veves A. (2004) The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 89: 740–747.
14. Foody J.M. Mendys P.M. Liu L.Z. Simpson R.J. Jr (2010) The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med 122: 222–229.
15. Fujino H. Yamada I. Kojima J. (1999) Studies on the metabolic fate of NK- 104, a new inhibitor of HMG-CoA reductase. Xenobio Metabol Dispos 14: 415–424.
16. Fujino, H., Saito, T., Tsunenari, Y,. Kojima, J. and Sakaeda, T. (2004) Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34: 961–971
17. Fujino H. Yamada I. Shimada S. Yoneda M. Kojima J. (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: Human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33: 27–41.
18. Giroud D. Li J.M. Urban P. Meier B. Rutishauer W. (1992) Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 69: 729–732.
19. Go, A., Chertow, G.M., Fan, D., McCulloch, C.E. and Hsu, C.-Y. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305
20. Gordon T. Castelli W.P. Hjortland M.C. Kannel W.B. Dawber T.R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707–714.
21. Graham I. Atar D. Borch-Johnsen K. Boysen G. Burell G. Cifkova R. et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14(Suppl 2): S1–113.
22. Grundy S.M. Cleeman J.I. Merz C.N. Brewer H.B. Jr Clark L.T. Hunninghake D.B. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.
23. Han J. Zhou X. Yokoyama T. Hajjar D.P. Gotto A.M. Jr Nicholson A.C. (2004) Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 109: 790–796.
24. Hasunuma T. Masahiko N. Takashi Y. Noriko A. Kuniaki F. Hajime I. et al (2003) The drug–drug Interactions of pitavastatin (NK-104), a novel HMG-CoA reductase Inhibitor and cyclosporine. J Clin Ther Med 19: 381–389.
25. Hayashi T. Yokote K. Saito Y. Iguchi A. (2007) Pitavastatin: Efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 8: 2315–2327.
26. Heart Protection Study Collaborative Group. (2002) MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
27. Hiraoka M. Nitta N. Nagai M. Shimokado K. Yoshida M. (2004) MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci 75: 1333–1341.
28. Hiraoka M. Yoshida M. (2003) A novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK1/2-dependent but not STAT3-dependent signaling transduction. Circ J 67(Suppl 1): 271–272.
29. Hiro T. Kimura T. Morimoto T. Miyauchi K. Nakagawa Y. Yamagishi M. et al (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54: 293–302.
30. Hounslow N.J. Budinski D. Eriksson M. (2010) Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high risk primary hypercholesterolemia or combined dyslipidaemia. EAS 2010: abstract 890.
31. Igel M. Arnold K.A. Niemi M. Hofmann U. Schwab M. Lütjohann D. et al (2006) Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 79: 419–426.
32. Inagaki Y. Hunt T. Arana B. Gosho M. Morgan R. (2009) Drug–drug interaction study to assess the effects of multiple dose of pitavastatin on steady state warfarin in healthy adult volunteers. Atheroscler Suppl 10: e806–e806.
33. Inoue, I., Itoh, F., Aoyagi, S., Tazawa, S., Kusama, H., Akahane, M. et al. (2002) Fibrate and statin synergistically increase the transcriptional activities of PPARalpha / RXRalpha and decrease the transactivation of NFkappa B. Biochem Biophys Res Commun 290 (11): 131–139
34. Inoue K. Sugiyama A. Reid P.C. Ito Y. Miyauchi K. Mukai S. et al (2007) Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161–167.
35. Jacobson T.A. (2006) The safety of aggressive statin therapy: How much can low-density lipoprotein cholesterol be lowered? Mayo Clin Proc 81: 1225–1231.
36. Kawai T. Tokui M. Funae O. Meguro S. Yamada S. Tabata M. et al (2005) Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 28: 2980–2981.
37. Kawakami A. Tani M. Chiba T. Yui K. Shinozaki S. Nakajima K. et al (2005) Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB 48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol 25: 424–429.
38. Kawashiri M.A. Nohara A. Tada H. Mori M. Tsuchida M. Katsuda S. et al (2008) Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q 10 in heterozygous familial hypercholesterolemia: Results from a crossover study. Clin Pharmacol Ther 83: 731–739.
39. Kibayashi E. Urakaze M. Kobashi C. Kishida M. Takata M. Sato A. et al (2005) Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 108: 515–521.
40. Kimura K. Shimano H. Yokote K. Urashima M. Teramoto T. (2010) Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. J Atheroscler Thromb 30 (17): 601–609.
41. Kohno M. Shinomiya K. Abe S. Noma T. Kondo I. Oshita A. et al (2002) Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 25: 279–285.
42. Koshiyama H. Taniguchi A. Tanaka K. Kagimoto S. Fujioka Y. Hirata K. et al (2008) Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb 15: 345–350.
43. Kotseva K. Wood D. de Backer G. de Bacquer D. Pyörälä K. Keil U. (2009) EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Lancet 373: 929–940.
44. Kurihara Y. Douzono T. Kawakita K. Nagasaka Y. (2008) A large-scale, long-term prospective post-marketing surveillance of piavastatin (Livalo) – Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 36: 709–731.
45. LaRosa J.C. Grundy S.M. Waters D.D. Shear C. Barter P. Fruchart J.C. et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
46. Little W.C. (1990) Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 66: 44G–47G.
47. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357.
48. Markle R.A. Han J. Summers B.D. Yokoyama T. Hajjar K.A. Hajjar D.P. et al (2003) Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 90: 23–32.
49. Mathew P. Cuddy T. Tracewell W.G. Salazar D. (2004) An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther 75: P33–P33.
50. Meade L.T. (2007) Barriers to achieving LDL cholesterol goals. US Pharm 32: 66–71.
51. Mega J.L. Morrow D.A. Brown A. Cannon C.P. Sabatine M.S. (2009) Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29: 1310–1315.
52. Miller M. Cannon C.P. Murphy S.A. Qin J. Ray K.K. Braunwald E. (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51: 724–730.
53. Morikawa S. Takabe W. Mataki C. Kanke T. Itoh T. Wada Y. et al (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9: 178–183.
54. Morikawa S. Takabe W. Mataki C. Wada Y. Izumi A. Saito Y. et al (2004) Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11: 62–72.
55. Morikawa, S., Umetani, M., Nakagawa, S., Yamazaki, H., Suganami, H., Inoue, K. et al. (2000) Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 7: 138–144
56. Motomura T. Okamoto M. Kitamura T. Yamamoto H. Otsuki M. Asanuma N. et al (2009) Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 16: 546–552.
57. Mukhtar R.Y. Reid J. Reckless J.P. (2005) Pitavastatin. Int J Clin Pract 59: 239–252.
58. Nakano, K. and Egashira, K. (2009) Pitavastatin has most potent pro-healing effects on endothelial cells and inhibitory effects on proliferation of vascular smooth muscle cells – a potential treatment strategy for drug-eluting stents. In The 41st Annual Scientific Meeting of the Japan Atherosclerosis Society (July 2009) general presentation No. 21.
59. Nakaya N. Tateno M. Nakamura T. (2001) Pharmacokinetics of reported dose NK-104 (pitavastatin) in healthy elderly and non-elderly volunteers. J Clin Therap Med 17: 957–970.
60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002) Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 106: 3143–3421.
61. Neuvonen P.J. Niemi M. Backman J.T. (2006) Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565–581.
62. Nissen S.E. Nicholls S.J. Sipahi I. Libby P. Raichlen J.S. Ballantyne C.M. et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295: 1556–1565.
63. Nissen S.E. Tuzcu E.M. Schoenhagen P. Brown B.G. Ganz P. Vogel R.A. et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 1071–1080.
64. O'Donnell M.J., Xavier D., Liu L., Zhang H. Chin S.L. Rao-Melacini P. et al (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet 376: 112–123.
65. Ohbayashi H. Miyazawa C. Miyamoto K. Sagara M. Yamashita T. Onda R. (2009) Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 16: 490–500.
66. Ose L. Budinski D. Hounslow N.J. Arneson V. (2009) Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 25: 2755–2764.
67. Ose L. Budinski D. Hounslow N.J. Arneson V. (2010) Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210: 202–208.
68. Packard C.J. Ford I. Robertson M. Shepherd J. Blauw G.J. Murphy M.B. et al (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112: 3058–3065.
69. Pasterkamp G. Schoneveld A.H. van der Wal A.C. Hijnen D.J. van Wolveren W.J. Plomp S. et al (1999) Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. Arterioscler Thromb Vasc Biol 19: 54–58.
70. Pitavatstatin Prescribing Information. (2007) NK-104 Pitavastatin Investigators’ Brochure, Kowa Company: Tokyo.
71. Pitavatstatin Prescribing Information. (2010) Kowa Pharmaceuticals, America. www.kowapharma.com/documents/LIVALOpitavastatinprescribinginformationV1_220100131.pdf (accessed September 2010).
72. Polisecki E. Muallem H. Maeda N. Peter I. Robertson M. McMahon A.D. et al (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008: 109–114.
73. Ray K.K. Cannon C.P. Cairns R. Morrow D.A. Ridker P.M. Braunwald E. (2009) Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29: 424–430.
74. Ridker P.M. Genest J. Boekholdt S.M. Libby P. Gotto A.M. Nordestgaard B.G. et al (2010) HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial. Lancet 376: 333–339.
75. Ridker P.M. Cannon C.P. Morrow D. Rifai N. Rose L.M. McCabe C.H. et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28.
76. Ridker P.M. Danielson E. Fonseca F.A. Genest J. Gotto A.M. Jr Kastelein J.J. et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
77. Ridker P.M. Danielson E. Fonseca F.A. Genest J. Gotto A.M. Jr Kastelein J.J. et al (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175–1182.
78. Sagara N. Kawaji T. Takano A. Inomata Y. Inatani M. Fukushima M. et al (2007) Effect of pitavastatin on experimental choroidal neovascularization in rats. Exp Eye Res 84: 1074–1080.
79. Saito, Y. (2009) Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Man 5: 921–936
80. Saito Y. Yamada N. Teramoto T. Itakura H. Hata Y. Nakaya N. et al (2002) Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52: 251–255.
81. Sasaki J. Iwashita M. Kono S. (2006) Statins: Beneficial or adverse for glucose metabolism. J Atheroscler Thromb 13: 123–126.
82. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
83. Sever P.S. Dahlöf B. Poulter N.R. Wedel H. Beevers G. Caulfield M. et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149–1158.
84. Shalev, V., Chodick, G., Silber, H., Kokia, E., Jan, J. and Heymann, A.D. (2009) Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 169: 260–268
85. Sharma R.K. Singh V.N. Reddy H.K. (2009) Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag 5: 793–799.
86. Shepherd J. Cobbe S.M. Ford I. Isles C.G. Lorimer A.R. MacFarlane P.W. et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307.
87. Shitara Y. Sugiyama Y. (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112: 71–105.
88. Sommeijer D.W. MacGillavry M.R. Meijers J.C. van Zanten A.P. Reitsma P.H. Ten Cate H. (2004) Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27: 468–473.
89. Stender S. Hounslow N. (2009) Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler Suppl 10: P770–P770.
90. Suzuki, M., Iwasaki, H., Fujikawa, Y., Kitahara, M., Sakashita, M. and Sakoda, R. (2001) Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors. Bioorg Med Chem 9: 2727–2743
91. Suzuki H. Kobayashi H. Sato F. Yonemitsu Y. Nakashima Y. Sueishi K. (2003) Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 10: 109–116.
92. Sviridov D. Nestel P. Watts G. (2007) Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 5: 215–221.
93. Tamakawa T. Takano T. Tanaka S. Kadonosono K. Terauchi Y. (2008) Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 15: 269–275.
94. Tan K.C. Chow W.S. Tam S.C. Ai V.H. Lam C.H. Lam K.S. (2002) Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 87: 563–568.
95. Teramoto T. Sasaki J. Ueshima H. Egusa G. Kinoshita M. Shimamoto K. et al (2007) Executive summary of Japan Atherosclerosis Society JAS guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14: 45–50.
96. Teramoto T. Shimano H. Yokote K. Urashima M. (2009) Effects of pitavastatin (LIVALO tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 16: 654–661.
97. Thompson J.F. Man M. Johnson K.J. Wood L.S. Lira M.E. Lloyd D.B. et al (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5: 352–358.
98. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Brit Med J 317: 703–713.
99. Waters D.D. Brotons C. Chiang C.W. Ferrières J. Foody J. Jukema J.W. et al (2009) Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28–34.
100. Watson K.E. (2010) Pitavastatin: The newest HMG-CoA reductase inhibitor. Rev Cardiovasc Med 11: 26–32.
101. World Health Organization. (2010) Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Available at: www.who.int/diabetes/publications/en/ (accessed May 2010).
102. Yamazaki, H., Fujino, H. and Kanazawa, M. (2004) Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet). [In Japanese] Folia Pharmacol Jpn 123: 349–362
103. Yokote, K., Bujo, H., Hanaoka, H., Shinomiya, M., Miyashita, Y., Nishikawa, T. et al. (2008) Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients Collaborative study on hypercholesterolemia drug intervention and their bene?ts for atherosclerosis prevention (CHIBA study). Atheroscler 201: 345–352
104. Yokote K. Saito Y. (2009) Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: Subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 16: 297–298.
105. Yusuf S. Hawken S. Ounpuu S. Dans T. Avezum A. Lanas F. et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case–control study. Lancet 364: 937–952.